The market recorded a year-on-year growth of 237 per cent

India’s weight-loss drug market has grown into a ₹2,000-crore business within a year, powered by the launch of affordable generic versions of blockbuster medicines and rising acceptance of obesity treatment, according to a series of monthly industry reports by market research firm Pharmarack.

The reports suggested that India’s weight-loss drug market is moving beyond the initial excitement surrounding new launches. While growth has begun to moderate, the combination of rising awareness, wider availability of affordable generics and a growing burden of obesity and related diseases has established GLP-1 medicines as one of the fastest-growing segments of the country’s pharmaceutical industry. At the same time, experts say the market’s long-term success will depend not only on affordability and access but also on ensuring that these medicines are prescribed appropriately and used under medical supervision.

According to the report, the GLP-1 market, the class of medicines that includes semaglutide and tirzepatide, expanded from ₹565 crore in May 2025 to ₹1,906 crore by May 2026, before crossing ₹2,000 crore in June 2026. The market recorded a year-on-year growth of 237 per cent and a five-year compound annual growth rate (CAGR) of 97 per cent.

Newer Therapies

Dr Satish Chander Wasoori, senior consultant, Paras Hospital, Gurugram said India has a growing need for effective obesity management, and newer therapies are expanding the options available to both patients and healthcare professionals.

“As access improves and awareness increases, these medications have the potential to become an important part of holistic obesity care. We are also likely to see continued innovation with newer therapies, more personalized treatment strategies, and stronger integration of obesity management into routine healthcare. Ultimately, the goal is to improve overall metabolic health and quality of life, not just achieve weight loss,” he said. 

While the launch of tirzepatide and semaglutide injections sparked the initial surge, Pharmarack says the real turning point came with the entry of semaglutide generics in early 2026.

“The GLP-1 agonist market has more than tripled in turnover in the last one year,” said the April 2026 report. It added that generic medicines expanded the market by making treatment more affordable. Besides lower prices, the report attributes the growth to increasing awareness about obesity, wider acceptance of injectable medicines, partnerships by innovator companies to improve market reach and multiple generic launches at economical price points.

Innovator Presence

The reports suggested that generics did not merely take market share away from innovator brands but brought in new patients. By April 2026, the injectable GLP-1 market had become ten times larger than it was a year earlier. Innovator brands continued to retain a significant presence despite competition from lower-priced products.

The rapid expansion of the market also underscores the need for appropriate use, according to endocrinologists. “These medicines are not a quick solution. While they have been available for a few years and their commonly recognised side effects are known, more long-term data and clinical experience will help build a better understanding of their long-term safety and use,” said Dr SK Wangnoo, senior consultant, Endocrinology, Apollo Indraprastha Hospital.

He added that the medicines should be prescribed only to patients who meet appropriate medical criteria and used as part of a comprehensive, medically supervised approach to obesity management rather than for short-term cosmetic weight loss.

The rise of obesity medicines also mirrors a broader shift in India’s pharmaceutical market. Pharmarack’s February 2026 report found that chronic and sub-chronic therapies now account for 56 per cent of the Indian Pharmaceutical Market, reflecting the growing burden of non-communicable diseases such as obesity, diabetes and cardiovascular disorders. The report projects these diseases to account for nearly 70 per cent of India’s disease burden, indicating sustained demand for long-term therapies.

Published on July 23, 2026